Novo Nordisk restores enough Wegovy supply to meet prescriptions in US

Following issues at a contract manufacturer, Danish pharmaceutical firm Novo Nordisk had to announce that the supply for obesity drug Wegovy would be limited for some time. Now, the company has restored the supply to meet issued prescriptions in the US.

Photo: Novo Nordisk / PR

Novo Nordisk announces on its US website that the the supply of weight loss treatment Wegovy has been restored for all five available dose strengths for patients in the US who have already been prescribed the drug.

This means that patients currently undergoing treatment can continue their dose schedule without disruptions.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs